https://scholars.lib.ntu.edu.tw/handle/123456789/580013
標題: | Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240 | 作者: | Ryoo B.-Y. Merle P. Kulkarni A.S. ANN-LII CHENG Bouattour M. Lim H.Y. Breder V. Edeline J. Chao Y. Ogasawara S. Yau T. Garrido M. Chan S.L. Daniele B. Norquist J.M. Chen E. Siegel A.B. Zhu A.X. Finn R.S. Kudo M. |
關鍵字: | hepatocellular carcinoma; immunotherapy; patient-reported outcome measures; pembrolizumab; quality of life | 公開日期: | 2021 | 出版社: | John Wiley and Sons Inc | 卷: | 127 | 期: | 6 | 起(迄)頁: | 865-874 | 來源出版物: | Cancer | 摘要: | Background: Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC) vers |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096702993&doi=10.1002%2fcncr.33317&partnerID=40&md5=2afb97255cd8773db5854fe3a946987e https://scholars.lib.ntu.edu.tw/handle/123456789/580013 |
ISSN: | 0008-543X | DOI: | 10.1002/cncr.33317 | SDG/關鍵字: | pembrolizumab; placebo; monoclonal antibody; pembrolizumab; abdominal swelling; adult; advanced cancer; Article; cancer palliative therapy; controlled study; deterioration; drug efficacy; drug safety; European Organization for Research and Treatment of Ca |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。